Adzenys Xr-odt Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Mechanism of Action
Adzenys Xr-odt Indications
Indications
Adzenys Xr-odt Dosage and Administration
Adults and Children
Do not substitute for other amphetamine products on a mg-per-mg basis. <6yrs: not established. Individualize. Take in the AM. 6–17yrs: initially 6.3mg once daily; increase in increments of 3.1mg or 6.3mg at weekly intervals; max 18.8mg/day (6–12yrs) or max 12.5mg/day (13–17yrs). ≥18yrs: 12.5mg once daily. Switching from other amphetamine products: see full labeling.
Adzenys Xr-odt Contraindications
Contraindications
Adzenys Xr-odt Boxed Warnings
Boxed Warning
Abuse, misuse, and addiction.
Adzenys Xr-odt Warnings/Precautions
Warnings/Precautions
High potential for abuse, misuse, and addiction; assess patient's risk before prescribing. Assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, or other cardiac disease. Pre-existing psychotic disorder. Bipolar disorder. Screen for risk factors in developing manic episode prior to initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for serotonin syndrome; discontinue if occurs. Assess family history and evaluate for tics or Tourette’s syndrome before initiating; monitor for emergence or worsening, and discontinue if clinically appropriate. Peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. Monitor BP, HR, growth in children. Write ℞ for smallest practical amount. Reevaluate periodically. Labor & delivery. Pregnancy: monitor for neonatal withdrawal symptoms. Nursing mothers: not recommended.
Adzenys Xr-odt Pharmacokinetics
Absorption
Mean peak plasma concentrations: 44.9 (±8.9) ng/mL occurred at a median time of 5.0 hours (dextroamphetamine); 14.5 (+3.0) ng/mL occurred at a median time of 5.25 hours (levoamphetamine).
Elimination
Renal. Half-life (dextroamphetamine): 11 hours in adults; 9–10 hours in pediatrics aged 6–12 years; (levoamphetamine): 14 hours in adults; 10–11 hours in pediatrics aged 6–12 years.
Adzenys Xr-odt Interactions
Interactions
Adzenys Xr-odt Adverse Reactions
Adverse Reactions
Adzenys Xr-odt Clinical Trials
See Literature
Adzenys Xr-odt Note
Notes
Adzenys Xr-odt Patient Counseling
See Literature
Images
